Trials / Conditions / Growth Hormone Disorder

Growth Hormone Disorder

38 registered clinical trials studyying Growth Hormone Disorder.

Status	Trial	Sponsor	Phase
Completed	Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan NCT03212131	Novo Nordisk A/S	Phase 1
Completed	Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan NCT03186495	Novo Nordisk A/S	Phase 1
Completed	A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® Flex NCT03075644	Novo Nordisk A/S	Phase 3
Completed	Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treat NCT02616562	Novo Nordisk A/S	Phase 2
Completed	A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Wee NCT02382939	Novo Nordisk A/S	Phase 3
Completed	Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® NCT02229851	Novo Nordisk A/S	Phase 3
Completed	Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone NCT02005198	Novo Nordisk A/S	—
Completed	A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-act NCT01973244	Novo Nordisk A/S	Phase 1
Completed	A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long- NCT01706783	Novo Nordisk A/S	Phase 1
Completed	First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects NCT01514500	Novo Nordisk A/S	Phase 1
Completed	Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated NCT01327924	Novo Nordisk A/S	—
Completed	Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents NCT01245374	Novo Nordisk A/S	Phase 4
Withdrawn	An Observational Study on Treatment Compliance by Children Treated With Growth Hormone NCT01068639	Novo Nordisk A/S	—
Completed	Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficienc NCT01109017	Novo Nordisk A/S	—
Completed	A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacody NCT00936403	Novo Nordisk A/S	Phase 2
Completed	An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditrop NCT00934063	Novo Nordisk A/S	—
Completed	Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-008 NCT00722540	Novo Nordisk A/S	Phase 1
Completed	Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of N NCT00715689	Novo Nordisk A/S	Phase 2
Completed	Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compare NCT01034202	Novo Nordisk A/S	Phase 1
Completed	Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™ NCT01500486	Novo Nordisk A/S	—
Completed	Observational Prospective Study on Patients Treated With Norditropin® NCT00960128	Novo Nordisk A/S	—
Completed	Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome NCT01604161	Novo Nordisk A/S	—
Completed	Long-term Trial on Growth Hormone Deficiency in Adults (GHDA) NCT00184730	Novo Nordisk A/S	Phase 3
Completed	Long-term Trial on Growth Hormone Deficiency in Adults (GHDA) NCT00184743	Novo Nordisk A/S	Phase 3
Completed	French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin NCT01580605	Novo Nordisk A/S	—
Completed	Safety and Efficacy of Long-term Somatropin Treatment in Adults NCT01543880	Novo Nordisk A/S	—
Completed	Growth Hormone Deficiency in Adults (GHDA) NCT00519558	Novo Nordisk A/S	Phase 3
Completed	Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children NCT00102817	Novo Nordisk A/S	Phase 3
Completed	Liquid Somatropin Formulation in Children With Growth Hormone Deficiency NCT00567385	Novo Nordisk A/S	Phase 4
Completed	An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Pres NCT01009905	Novo Nordisk A/S	—
Completed	Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficien NCT00184678	Novo Nordisk A/S	Phase 3
Terminated	Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency NCT01698944	Novo Nordisk A/S	Phase 4
Completed	Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency NCT01502124	Novo Nordisk A/S	Phase 3
Completed	Safety and Efficacy of Long-term Somatropin Treatment in Children NCT01543867	Novo Nordisk A/S	—
Completed	Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency NCT01563926	Novo Nordisk A/S	Phase 3
Completed	Effect of Growth Hormone in Children With Growth Hormone Deficiency NCT00262249	Novo Nordisk A/S	Phase 3
Completed	A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatrop NCT00931476	Novo Nordisk A/S	Phase 1
Completed	Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients NCT01562834	Novo Nordisk A/S	Phase 4